OnKure Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
OKUR$2.87+13.5%Stored close · as of Nov 6, 2026
Contents
Consolidated Balance Sheets
(In thousands, except share and par value data)
| September 30,2024 | December 31,2023 | |
|---|---|---|
| (Unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $60,689 | $27,632 |
| Short-term investments | 15,979 | 75,331 |
| Prepaid expenses and other current assets | 331 | 3,659 |
| Total current assets | 76,999 | 106,622 |
| Property and equipment, net | 59 | 134 |
| Right-of-use assets | 440 | 599 |
| Other non-current assets | 147 | 81 |
| Total assets | $77,645 | $107,436 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $237 | $8,717 |
| Accrued expenses | 725 | 9,129 |
| Private placement deposit | 2,000 | — |
| Operating lease liabilities, current portion | 286 | 331 |
| Total current liabilities | 3,248 | 18,177 |
| Operating lease liabilities, less current portion | 379 | 642 |
| Performance award | — | 7 |
| Total liabilities | 3,627 | 18,826 |
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Common stock, $0.0001 par value; 200,000,000 shares authorized at September 30, 2024 and December 31, 2023; 3,343,525 shares issued and outstanding at September 30, 2024 and 3,342,034 shares issued and outstanding at December 31, 2023, respectively | — | — |
| Additional paid-in capital | 309,969 | 307,076 |
| Accumulated deficit | (235,953) | (218,474) |
| Accumulated other comprehensive income | 2 | 8 |
| Total stockholders’ equity | 74,018 | 88,610 |
| Total liabilities and stockholders’ equity | $77,645 | $107,436 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.